ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1801

Biological Roles of C5orf30 in Rheumatoid Arthritis

Munitta Muthana1, Sachin Khetan2, Gbadebo Adeleke Adeleke3, Simon Tazzyman3, Sarah Aynsley1, Fiona Morrow1, Sarah Hawtree1, Barbara Ciani4 and Anthony G. Wilson1, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Infection and immunity, Dr, Sheffield, United Kingdom, 3Infection and Immunity, Dr, Sheffield, United Kingdom, 4Chemistry, University of Sheffield, Sheffield, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: macrophages

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

A recent genome wide association study identified the variant rs26232 in the first exon of an uncharacterized gene C5orf30. In addition, this variant is also associated with severity of radiological joint damage suggesting a role in tissue breakdown. To date there is no function assigned for C5orf30 and neither the gene or protein coded show homology to any known functional sequences. However, C5orf30 is highly conserved in chimpanzee, dog, cow, mouse, chicken, and zebrafish (orthologs). The aim of this study is to determine the biological roles of C5orf30 in health and RA.

Methods:

Real time PCR and western blotting was used to determine C5orf30 transcript and protein levels in fibroblast-like synovial cells (FLS-stimulated with TNF & hypoxia) and peripheral blood leukocytes isolated from RA patients and healthy individuals.  Immunohistochemistry using synovial samples was used to determine cellular expression using anti-C5orf30 and antibodies to macrophages (CD68), fibroblasts (5B5), T (CD3) & B (CD19) cells.  To investigate gene function siRNA was used to knockdown C5orf30 in synovial FLS in vitro and we have used morpholino antisense oligonucleotide (MO)-mediated knocked down of C5orf30 in zebrafish embryos (fms:mcherry) in vivo.

Results:

Expression of C5orf30 was detected at lower levels in peripheral blood leukocytes of RA patients compared to healthy controls (117 patients vs. 102 controls, p=0.00052).  C5orf30 was expressed in joint FLS and was found to be up regulated following treatment with hypoxia (8-fold) and down-regulated by TNF-a (0.5-fold).  Confocal microscopy revealed C5orf30 was strongly expressed in both the nuclear and cytoplasmic compartment of synovial lining cells including macrophages and fibroblasts but not B & T cells. C5orf30 was undetectable in arthroscopy sections obtained from osteoarthritis or control (knee replacement) patients. So far, 80% C5orf30 knockdown has been achieved in FLS without affecting cell viability.  Interestingly, MO-mediated knockdown of C5orf30 impeded zebrafish development and increased total macrophage numbers by 40% compared to knockdown of a scrambled control MO.

Conclusion:

C5orf30 is expressed at both the transcript & protein level in synovial cells but not in circulating PBMC obtained from RA patients, suggesting that C5orf30 is expressed in a tissue-specific manner. We are currently assessing the morphological phenotype and function arising from C5orf30 siRNA knockdown in FLS using confocal microscopy and matrigel invasion assays. NMR and mass spectrometry experiments are on the way to determine the three-dimensional structure of C5orf30 and its potential protein-binding partners.


Disclosure:

M. Muthana,
None;

S. Khetan,
None;

G. A. Adeleke,
None;

S. Tazzyman,
None;

S. Aynsley,
None;

F. Morrow,
None;

S. Hawtree,
None;

B. Ciani,
None;

A. G. Wilson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biological-roles-of-c5orf30-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology